PDF(Pubmed)
Abstract：
Coronary heart disease (CHD) is a serious cardiovascular illness, for which an elevated uric acid (UA) level presents as a considerable risk factor. This can be treated with UA-lowering drugs such as allopurinol and benzbromarone, which can reduce UA levels by the inhibition of UA production or by promoting its excretion. Such drugs can also be beneficial to CHD in other ways, such as reducing the degree of coronary arteriosclerosis, improving myocardial blood supply and alleviating ventricular remodeling. Different UA-lowering drugs are used in different ways: allopurinol is preferred as a single agent in clinical application, but in absence of the desired response, a combination of drugs such as benzbromarone with ACE inhibitors may be used. Patients must be monitored regularly to adjust the medication regimen. Appropriate use of UA-lowering drugs has great significance for the prevention and treatment of CHD. However, the specific mechanisms of the drugs and individualized drug use need further research. This review article expounds the mechanisms of UA-lowering drugs on CHD and their clinical application strategy, thereby providing a reference for further optimization of treatment.
摘要：
冠心病(CHD)是一种严重的心血管疾病,尿酸（UA）水平升高是一个相当大的危险因素。这可以用降低UA的药物治疗，如别嘌呤醇和苯溴马隆，可以通过抑制UA产生或通过促进其排泄来降低UA水平。这些药物也可以在其他方面对冠心病有益，比如降低冠状动脉硬化的程度，改善心肌供血，减轻心室重构。不同降尿酸药物的使用方式不同：别嘌呤醇作为单药在临床应用中首选，但是在没有期望的反应的情况下，可以使用药物如苯溴马隆与ACE抑制剂的组合。必须定期监测患者以调整用药方案。合理使用降尿酸药物对冠心病的防治具有重要意义。然而,药物的具体作用机制和个体化用药需要进一步研究。本文就降UA药物治疗冠心病的作用机制及其临床应用策略进行综述。从而为进一步优化治疗提供参考。
